The FDA has approved Intellia Therapeutics’ in vivo CRISPR therapy for hereditary angioedema, clearing lonvoguran ziclumeran (lonvo-z) after a successful Phase 3 program. The approval supports a one-dose genome-editing approach using an mRNA-lipid nanoparticle (LNP) platform, targeting a rare disease marked by unpredictable, sometimes life-threatening swelling attacks. Reporting around the BLA also highlights the clinical context for HAE patients, including the day-to-day unpredictability of attacks and quality-of-life disruption. Lead investigator Danny Cohn of Amsterdam University Medical Center and independent clinician Kelsey Uminski of the University of Calgary emphasized that while existing therapies reduce attack frequency for many, side effects and unpredictability remain unmet needs. For biotech operators, the decision reinforces momentum for in vivo gene editing—specifically LNP-delivered nucleic-acid approaches—moving it further from clinical validation toward broader treatment planning and adoption in rare immune disorders.